Selected article for: "active form and Remdesivir triphosphate form"
Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response
  • Document date: 2020_4_14
    • ID: d7stppv5_51
    Snippet: We employed ordinary differential equation models to analyze the in-host SARS CoV-2 dynamics in infected individuals and the potential in vivo effect of different treatment strategies. First, we fit models to the viral load data from different sources using a nonlinear-mixed effects approach. Second, we used pharmacokinetics models to fits observed plasma concentration of remdesivir (RDV) and its active nucleoside triphosphate form in PBMCs, and .....
    Document: We employed ordinary differential equation models to analyze the in-host SARS CoV-2 dynamics in infected individuals and the potential in vivo effect of different treatment strategies. First, we fit models to the viral load data from different sources using a nonlinear-mixed effects approach. Second, we used pharmacokinetics models to fits observed plasma concentration of remdesivir (RDV) and its active nucleoside triphosphate form in PBMCs, and blood concentration of hydroxychloroquine (HCQ). Third, we simulated dose response curves for antiviral effect of RDV and HCQ using different possible half maximal effective concentration (EC50) based on in-vitro estimations against SARS-CoV-2. Fourth, we simulated therapy at different times during infection to analyze the potential reduction of SARS CoV-2 shedding. Finally, we repeated projections of therapy including the emergence of resistance to therapy.

    Search related documents:
    Co phrase search for related documents
    • active nucleoside PBMCs triphosphate form and nucleoside PBMCs triphosphate form: 1, 2, 3
    • active nucleoside PBMCs triphosphate form and PBMCs triphosphate form: 1, 2, 3
    • active nucleoside PBMCs triphosphate form and plasma concentration: 1
    • active nucleoside PBMCs triphosphate form and triphosphate form: 1, 2, 3
    • antiviral effect and blood concentration: 1, 2
    • antiviral effect and different source: 1, 2
    • antiviral effect and different time: 1, 2, 3, 4, 5, 6, 7
    • antiviral effect and differential equation model: 1
    • antiviral effect and effective concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • antiviral effect and equation model: 1
    • antiviral effect and half maximal effective concentration: 1, 2
    • antiviral effect and HCQ hydroxychloroquine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • antiviral effect and infected individual: 1, 2
    • antiviral effect and ordinary differential equation model: 1
    • antiviral effect and pharmacokinetic model: 1, 2
    • antiviral effect and plasma concentration: 1, 2, 3, 4, 5, 6
    • antiviral effect and potential reduction: 1
    • antiviral effect and resistance emergence: 1, 2, 3
    • antiviral effect and treatment strategy: 1, 2, 3, 4, 5, 6, 7